KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $57,981,144 | -31.0% | 1,268,734 | 0.0% | 1.14% | -25.6% |
| Q1 2024 | $83,990,191 | +66.5% | 1,268,734 | 0.0% | 1.54% | +52.7% |
| Q4 2023 | $50,444,864 | +4.5% | 1,268,734 | -16.2% | 1.01% | -1.9% |
| Q3 2023 | $48,289,720 | -20.7% | 1,514,734 | 0.0% | 1.03% | -7.0% |
| Q2 2023 | $60,862,012 | -15.1% | 1,514,734 | -9.8% | 1.10% | -21.7% |
| Q1 2023 | $71,711,106 | -11.1% | 1,679,417 | 0.0% | 1.41% | -8.7% |
| Q4 2022 | $80,645,604 | +27.6% | 1,679,417 | 0.0% | 1.54% | +31.5% |
| Q3 2022 | $63,180,000 | +36.2% | 1,679,417 | 0.0% | 1.17% | +39.5% |
| Q2 2022 | $46,402,000 | -49.2% | 1,679,417 | 0.0% | 0.84% | -43.2% |
| Q1 2022 | $91,327,000 | -7.1% | 1,679,417 | 0.0% | 1.48% | +17.3% |
| Q4 2021 | $98,263,000 | +47.9% | 1,679,417 | 0.0% | 1.26% | +73.0% |
| Q3 2021 | $66,438,000 | -6.9% | 1,679,417 | 0.0% | 0.73% | +1.2% |
| Q2 2021 | $71,325,000 | -31.0% | 1,679,417 | 0.0% | 0.72% | -25.4% |
| Q1 2021 | $103,368,000 | -12.7% | 1,679,417 | 0.0% | 0.97% | -6.8% |
| Q4 2020 | $118,466,000 | +82.9% | 1,679,417 | 0.0% | 1.04% | +27.4% |
| Q3 2020 | $64,775,000 | +2.8% | 1,679,417 | 0.0% | 0.81% | -8.2% |
| Q2 2020 | $62,995,000 | – | 1,679,417 | – | 0.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 292,833 | $17,134,000 | 5.65% |
| Deep Track Capital, LP | 1,300,000 | $76,063,000 | 5.37% |
| Octagon Capital Advisors LP | 340,214 | $19,906,000 | 3.87% |
| Opaleye Management Inc. | 265,750 | $15,549,000 | 3.30% |
| First Light Asset Management, LLC | 552,098 | $32,303,000 | 2.31% |
| Altium Capital Management LP | 116,000 | $6,787,000 | 1.87% |
| Nantahala Capital Management | 796,698 | $46,615,000 | 1.64% |
| Orbimed Advisors | 1,679,417 | $98,263,000 | 1.26% |
| Darwin Global Management, Ltd. | 111,500 | $6,524,000 | 1.00% |
| Parkman Healthcare Partners LLC | 69,861 | $4,088,000 | 0.90% |